Search

Your search keyword '"Morgan, Charity J"' showing total 282 results
Start Over Author "Morgan, Charity J" Language english
282 results on '"Morgan, Charity J"'

3. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial

Author

Bourdette, Dennis, Yadav, Vijayshree, Goodman, Andrew, Racke, Michael, Fallis, Robert, Tornatore, Carlo, Goldman, Myla, Kannan, Meena, Sriram, Subramaniam, Berger, Joseph, Cross, Anne, Rammohan, Kottil, Xia, Zongqi, Leist, Thomas, Lynch, Sharon, Klawiter, Eric, Amezcua, Lilyana, Bowen, James, Corboy, John R, Fox, Robert J, Kister, Ilya, Cutter, Gary R, Morgan, Charity J, Seale, Rebecca, Engebretson, Eric, Gustafson, Tarah, and Miller, Aaron E

Published
2023
Full Text
View/download PDF

16. Targeted Treatment of Individuals With Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase Gene

Author

Bodkin, J. Alexander, Coleman, Michael J., Godfrey, Laura J., Carvalho, Claudia M.B., Morgan, Charity J., Suckow, Raymond F., Anderson, Thea, Öngür, Dost, Kaufman, Marc J., Lewandowski, Kathryn E., Siegel, Arthur J., Waldstreicher, Elliot, Grochowski, Christopher M., Javitt, Daniel C., Rujescu, Dan, Hebbring, Scott, Weinshilboum, Richard, Rodriguez, Stephanie Burgos, Kirchhoff, Colette, Visscher, Timothy, Vuckovic, Alexander, Fialkowski, Allison, McCarthy, Shane, Malhotra, Dheeraj, Sebat, Jonathan, Goff, Donald C., Hudson, James I., Lupski, James R., Coyle, Joseph T., Rudolph, Uwe, and Levy, Deborah L.

Published
2019
Full Text
View/download PDF

24. Myocardial perfusion imaging: Lessons learned and work to be done—update

Author

Iskandrian, Ami E., Dilsizian, Vasken, Garcia, Ernest V., Beanlands, Rob S., Cerqueira, Manuel, Soman, Prem, Berman, Daniel S., Cuocolo, Alberto, Einstein, Andrew J., Morgan, Charity J., Hage, Fadi G., Schelbert, Heinrich R., Bax, Jeroen J., Wu, Joseph C., Shaw, Leslee J., Sadeghi, Mehran M., Tamaki, Nagara, Kaufmann, Philipp A., Gropler, Robert, Dorbala, Sharmila, and Van Decker, William

Published
2018
Full Text
View/download PDF

28. Systolic–diastolic hypertension versus isolated systolic hypertension and incident heart failure in older adults: Insights from the Cardiovascular Health Study

Author

Tsimploulis, Apostolos, Sheriff, Helen M., Lam, Phillip H., Dooley, Daniel J., Anker, Markus S., Papademetriou, Vasilios, Fletcher, Ross D., Faselis, Charles, Fonarow, Gregg C., Deedwania, Prakash, White, Michel, Valentova, Miroslava, Blackman, Marc R., Banach, Maciej, Morgan, Charity J., Alagiakrishnan, Kannayiram, Allman, Richard M., Aronow, Wilbert S., Anker, Stefan D., and Ahmed, Ali

Published
2017
Full Text
View/download PDF

31. Identification and outcomes of KDIGO‐defined chronic kidney disease in 1.4 million U.S. Veterans with heart failure.

Author

Patel, Samir S., Raman, Venkatesh K., Zhang, Sijian, Deedwania, Prakash, Zeng‐Treitler, Qing, Wu, Wen‐Chih, Lam, Phillip H., Bakris, George, Moore, Hans, Heidenreich, Paul A., Rangaswami, Janani, Morgan, Charity J., Cheng, Yan, Sheriff, Helen M., Faselis, Charles, Mehta, Ravindra L., Anker, Stefan D., Fonarow, Gregg C., and Ahmed, Ali

Subjects
CHRONIC kidney failure, CHRONICALLY ill, VETERANS, HEART failure, RENAL replacement therapy, GLOMERULAR filtration rate, HEART failure patients
Abstract

Aims: According to the Kidney Disease: Improving Global Outcomes (KDIGO) guideline, the definition of chronic kidney disease (CKD) requires the presence of abnormal kidney structure or function for >3 months with implications for health. CKD in patients with heart failure (HF) has not been defined using this definition, and less is known about the true health implications of CKD in these patients. The objective of the current study was to identify patients with HF who met KDIGO criteria for CKD and examine their outcomes. Methods and results: Of the 1 419 729 Veterans with HF not receiving kidney replacement therapy, 828 744 had data on ≥2 ambulatory serum creatinine >90 days apart. CKD was defined as estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m2 (n = 185 821) or urinary albumin‐to‐creatinine ratio (uACR) >30 mg/g (n = 32 730) present twice >3 months apart. Normal kidney function (NKF) was defined as eGFR ≥60 ml/min/1.73 m2, present for >3 months, without any uACR >30 mg/g (n = 365 963). Patients with eGFR <60 ml/min/1.73 m2 were categorized into four stages: 45–59 (n = 72 606), 30–44 (n = 74 812), 15–29 (n = 32 077), and <15 (n = 6326) ml/min/1.73 m2. Five‐year all‐cause mortality occurred in 40.4%, 57.8%, 65.6%, 73.3%, 69.7%, and 47.5% of patients with NKF, four eGFR stages, and uACR >30mg/g (albuminuria), respectively. Compared with NKF, hazard ratios (HR) (95% confidence intervals [CI]) for all‐cause mortality associated with the four eGFR stages and albuminuria were 1.63 (1.62–1.65), 2.00 (1.98–2.02), 2.49 (2.45–2.52), 2.28 (2.21–2.35), and 1.22 (1.20–1.24), respectively. Respective age‐adjusted HRs (95% CIs) were 1.13 (1.12–1.14), 1.36 (1.34–1.37), 1.87 (1.84–1.89), 2.24 (2.18–2.31) and 1.19 (1.17–1.21), and multivariable‐adjusted HRs (95% CIs) were 1.11 (1.10–1.12), 1.24 (1.22–1.25), 1.46 (1.43–1.48), 1.42 (1.38–1.47), and 1.13 (1.11–1.16). Similar patterns were observed for associations with hospitalizations. Conclusion: Data needed to define CKD using KDIGO criteria were available in six out of ten patients, and CKD could be defined in seven out of ten patients with data. HF patients with KDIGO‐defined CKD had higher risks for poor outcomes, most of which was not explained by abnormal kidney structure or function. Future studies need to examine whether CKD defined using a single eGFR is characteristically and prognostically different from CKD defined using KDIGO criteria. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. A multicenter prospective study to define the natural history of BK viral infections in kidney transplantation.

Author

Seifert, Michael E., Mannon, Roslyn B., Nellore, Anoma, Young, JoAnne, Wiseman, Alexander C., Cohen, David J., Peddi, V. Ram, Brennan, Daniel C., Morgan, Charity J., Peri, Kalyani, Aban, Inmaculada, Whitley, Richard J., and Gnann, John W.

Subjects
BK virus, KIDNEY transplantation, VIRUS diseases, LONGITUDINAL method, VIRAL load, RACE
Abstract

Background: BK polyomavirus (BKV) can cause permanent loss of allograft function due to BKV‐associated nephropathy (BKVN) in kidney transplant recipients. Besides immunosuppression reduction, there are no consistently effective interventions for BKV infection. Study purpose was to define natural history of BKV infection, identify risk factors for BKV reactivation and BKVN in kidney transplant recipients, and inform the design/conduct of future clinical trials of BKV‐targeted therapeutics. Methods: We conducted a multicenter prospective observational study of incident kidney transplant recipients at six U.S. transplant centers. Participants were monitored every 4 weeks for BKV reactivation and followed for up to 24 months post‐transplant. We used regression models (logistic, survival, mixed models) to study relationships between BK viremia/BKVN, clinical characteristics, and allograft function. Results: We enrolled 335 participants. Fifty‐eight (17%) developed BK viremia, 6 (2%) developed biopsy‐proven BKVN, and 29 (9%) developed suspected/presumed BKVN (defined as BKV viral load > 10,000 copies/mL without biopsy). Male donor sex was associated with lower odds for BK viremia, whereas recipient Black race was associated with two‐fold increased odds for BK viremia. Recipient female sex was associated with more rapid clearance of BK viremia. Persistent BK viremia/BKVN was associated with poorer allograft function by 24 months post‐transplant. Conclusions: We identified multiple donor and recipient demographic factors associated with risk for BKV infection and poorer allograft function by 24 months post‐transplant. This may help design future clinical trials of therapies to prevent or mitigate the deleterious impact of BKV reactivation on kidney transplant outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Lack of evidence of lower 30-day all-cause readmission in Medicare beneficiaries with heart failure and reduced ejection fraction discharged on spironolactone

Author

Lam, Phillip H., Dooley, Daniel J., Inampudi, Chakradhari, Arundel, Cherinne, Fonarow, Gregg C., Butler, Javed, Wu, Wen-Chih, Blackman, Marc R., Anker, Markus S., Deedwania, Prakash, White, Michel, Prabhu, Sumanth D., Morgan, Charity J., Love, Thomas E., Aronow, Wilbert S., Allman, Richard M., and Ahmed, Ali

Published
2017
Full Text
View/download PDF

43. Impact of the COVID-19 Pandemic on the Provision of Dialysis Service and Mortality in Veterans Receiving Maintenance Hemodialysis in the VA: An Interrupted Time-Series Analysis.

Author

Patel, Samir, Trujillo Rivera, Eduardo A., Raman, Venkatesh K., Faselis, Charles, Wang, Virginia, Fink, Jeffrey C., Roseman, Jeffrey M., Morgan, Charity J., Zhang, Sijian, Sheriff, Helen M., Heimall, Michael S., Wu, Wen-Chih, Zeng-Treitler, Qing, and Ahmed, Ali

Subjects
HEMODIALYSIS facilities, COVID-19 pandemic, TIME series analysis, HEALTH facilities, CHRONIC kidney failure, DIALYSIS (Chemistry)
Abstract

Introduction: According to the US Renal Data System (USRDS), patients with end-stage kidney disease (ESKD) on maintenance dialysis had higher mortality during early COVID-19 pandemic. Less is known about the effect of the pandemic on the delivery of outpatient maintenance hemodialysis and its impact on death. We examined the effect of pandemic-related disruption on the delivery of dialysis treatment and mortality in patients with ESKD receiving maintenance hemodialysis in the Veterans Health Administration (VHA) facilities, the largest integrated national healthcare system in the USA. Methods: Using national VHA electronic health records data, we identified 7,302 Veterans with ESKD who received outpatient maintenance hemodialysis in VHA healthcare facilities during the COVID-19 pandemic (February 1, 2020, to December 31, 2021). We estimated the average change in the number of hemodialysis treatments received and deaths per 1,000 patients per month during the pandemic by conducting interrupted time-series analyses. We used seasonal autoregressive moving average (SARMA) models, in which February 2020 was used as the conditional intercept and months thereafter as conditional slope. The models were adjusted for seasonal variations and trends in rates during the pre-pandemic period (January 1, 2007, to January 31, 2020). Results: The number (95% CI) of hemodialysis treatments received per 1,000 patients per month during the pre-pandemic and pandemic periods were 12,670 (12,525–12,796) and 12,865 (12,729–13,002), respectively. Respective all-cause mortality rates (95% CI) were 17.1 (16.7–17.5) and 19.6 (18.5–20.7) per 1,000 patients per month. Findings from SARMA models demonstrate that there was no reduction in the dialysis treatments delivered during the pandemic (rate ratio: 0.999; 95% CI: 0.998–1.001), but there was a 2.3% (95% CI: 1.5–3.1%) increase in mortality. During the pandemic, the non-COVID hospitalization rate was 146 (95% CI: 143–149) per 1,000 patients per month, which was lower than the pre-pandemic rate of 175 (95% CI: 173–176). In contrast, there was evidence of higher use of telephone encounters during the pandemic (3,023; 95% CI: 2,957–3,089), compared with the pre-pandemic rate (1,282; 95% CI: 1,241–1,324). Conclusions: We found no evidence that there was a disruption in the delivery of outpatient maintenance hemodialysis treatment in VHA facilities during the COVID-19 pandemic and that the modest rise in deaths during the pandemic is unlikely to be due to missed dialysis. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results